AUD $5.3m R&D Rebate Received
Filed with ASX · · 2 pages · English
SYDNEY Australia, 14 January 2026: Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce cash refund of AUD $5,339,202 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for the financial year ending 30 June 2025. The AUD $5,339,202 reflects R&D activities undertaken
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- RCE Awarded Advanced Overseas Finding up to A$85m
- Hong Kong Patent Granted for RECCE Anti-Infectives
- Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
- Patient Dosing Underway in Ph 3 Indonesia DFI Trial
- Preliminary Final Report
Later from Recce Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Appendix 4D and Interim Financial Report
- RCE Investor Webinar Presentation Deck
- Brazil Patent Granted for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals